The Cardiac & Vascular Institute First In Florida To Enroll Patients In New Clinical Trial Studying Limflow Therapy

Gainesville, FL – February 19, 2020 – The Cardiac & Vascular Institute (TCAVI) announced it
is the first in Florida to perform a successful procedure in the PROMISE II pivotal study of the
LimFlow Percutaneous Deep Vein Arterialization System for the treatment of “no option”
Chronic Limb-Threatening Ischemia, a severe form of peripheral artery disease that affects the
lower leg. The LimFlow System has been designated as part of the FDA’s Breakthrough Devices
program, as it treats a patient population with no commercially available options to avoid
amputation of their lower leg or foot. The first case was performed by The Cardiac & Vascular
Institute’s Interventional Cardiologist and Principle Investigator Arthur Lee, M.D., FACC at
North Florida Regional Medical Center on January 23, 2020.

Read the entire news release here: LimFlow Press Release Feb 2020